Plain-English translation of NCT06742567 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a severe anterior heart attack (a heart attack affecting the front of the heart), the heart muscle can become weakened and may develop dangerous blood clots inside it. This trial is testing whether apixaban, a blood thinner medication, can prevent these clots from forming when given along with standard heart attack treatment. The study will compare patients who receive this medication to those who receive standard care alone.
When a large anterior heart attack damages the heart muscle severely, blood clots can form inside the heart and potentially travel to the brain or other organs, causing a stroke or other serious complications. Doctors want to know if starting this medication early can safely prevent these clots and improve outcomes for patients in this high-risk situation.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to either receive the new blood thinner medication plus standard heart attack medications for four weeks, or standard care alone. You'll have a phone check-in at 2 weeks to discuss how you're feeling and any side effects, and a full in-person visit at 4 weeks with an ultrasound of your heart to see if any clots have formed. The main goal is to determine if this medication safely prevents dangerous blood clots in your heart.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
Pakistan